Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25816612 | 0.84 | GPR119 (0.47) | GPR119KDM4EHRH3LMNAMEN1 | |
| SCHEMBL30547525 | 0.84 | GPR119 (0.47) | GPR119KDM4EHRH3LMNAMEN1 | |
| SCHEMBL25296290 | 0.82 | GPR119 (0.71) | GPR119KDM4EHRH3LMNARIPK1 | |
| SCHEMBL30547499 | 0.82 | GPR119 (0.71) | GPR119KDM4EHRH3LMNARIPK1 | |
| SCHEMBL25818904 | 0.81 | GPR119 (0.45) | GPR119KDM4EHRH3LMNAMEN1 | |
| SCHEMBL30339500 | 0.80 | KDM4E (0.50) | KDM4ELMNARIPK1CHRM4CHRM2 | |
| SCHEMBL25295118 | 0.80 | KDM4E (0.50) | KDM4ELMNARIPK1CHRM4CHRM2 | |
| Trifluoroacetic Acid SCHEMBL30338724 | 0.78 | GPR119 (0.41) | GPR119KDM4ELMNAL3MBTL1 | |
| SCHEMBL30441471 | 0.76 | KDM4E (0.43) | GPR119KDM4EHRH3LMNAMEN1 | |
| SCHEMBL25184918 | 0.76 | KDM4E (0.43) | GPR119KDM4EHRH3LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116547281-A | Isoxazolidines as RIPK1 inhibitors and uses thereof | 赛诺菲 | 2023-08-04 | — | — | CN | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | GPR119 420/4885KDM4E 2270/4885HRH3 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.